I saw out of the corner of my eye in scanning the news Tuesday that Abbott had been granted FDC approval for a CGM that does not require a prescription named Lingo. This makes lots of business sense since they already dominate the prescription CGM market for diabetics’ use of their Libre 3 System. Why not extend their reach into the much larger health-oriented market? BTW, Lingo is currently only available in the UK market. See this link.
From a larger perspective, Abbott and other such companies are going after much larger markets with biowearables. See the video below made in conjunction with CES 2023 for examples.
Leave a Reply